0.005% Latanoprost Gel for Nonsegmental Vitiligo

Launched by UNIVERSITAS PADJADJARAN · Jun 3, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a gel called 0.005% latanoprost for treating non-segmental vitiligo, a skin condition that causes loss of color in patches. Latanoprost is usually used to treat glaucoma but has shown promise in helping skin regain its pigment. The trial aims to see if this gel can safely help people with vitiligo achieve repigmentation of their skin, and it has shown positive results in previous studies without major side effects.

To participate in this trial, you need to be between 10 and 17 years old and have stable vitiligo for at least six months. You should have a couple of specific skin areas affected by vitiligo, which must be similar in size and located on both sides of your body. However, you cannot be using other treatments for your skin condition or have certain health issues, like other autoimmune diseases or allergies to the study medication. If you qualify, you can expect to use the gel on your skin and be monitored for its effects over time. This trial is still in the planning stages and has not started recruiting participants yet.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with non-segmental vitiligo.
• • Patients with stable vitiligo for at least 6 months based on the Vitiligo Disease Activity (VIDA) score.
• • Aged 10-17 years.
• • Affected area \<10%.
• * Having at least two lesions to be treated. The vitiligo lesions selected for treatment must meet the following criteria:
• • 1. Relatively the same size, ranging from a minimum of 1 cm² to 4 cm².
• • 2. Bilateral location on both sides of the body.
• • 3. A minimum distance of 5 cm between the studied lesions and other vitiligo lesions.
• • 4. Not located on the palms, soles, or genital area.
• Exclusion Criteria:
• • Use of topical therapy (corticosteroids, calcineurin inhibitors, psoralen, and antioxidants) for at least 2 weeks before the study, systemic therapy (corticosteroids, antioxidants, and vitamin D) for at least 4 weeks before the study, and phototherapy for at least 4 weeks before the study.
• • Presence of other active autoimmune diseases such as type 1 diabetes mellitus, thyroid disease, alopecia areata, rheumatoid arthritis, or Addison's disease, based on medical history and physical examination.
• • History of or current skin cancer, photosensitivity, or undergoing radiotherapy.
• • Allergy or contraindication to topical corticosteroids or latanoprost.
• • History of hypertension, asthma, diabetes mellitus, anemia, kidney, liver, neurological, or cardiovascular diseases.